PUBLICATIONS Choose Year All Years 2022 (1) 2020 (2) 2019 (1) 2018 (1) 2017 (2) Search Publications Found 7 Results February 25, 2022 Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia January 28, 2020 Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial January 1, 2020 Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression June 29, 2019 Letter to the Editor: Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial May 1, 2018 Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial December 29, 2017 The brief negative symptom scale (BNSS): Sensitivity to treatment effects July 28, 2017 Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia
